2026 Urethral carcinoma indication strategy covering epidemiology, FGFR3 biology, active trials, transactions, unmet need, competition and market attractiveness.

2026 Vulvar Paget disease indication strategy covering epidemiology, HER2 biology, active trials, transactions, unmet need, competition and market attractiveness.

2026 Vulvar melanoma indication strategy covering epidemiology, KIT biology, active trials, transactions, unmet need, competition and market attractiveness.

2026 Mesonephric adenocarcinoma indication strategy covering epidemiology, KRAS biology, active trials, transactions, unmet need, competition and market…

2026 Glass cell carcinoma of cervix indication strategy covering epidemiology, PD-1 biology, active trials, transactions, unmet need, competition and market…

2026 Adenomatoid tumor indication strategy covering epidemiology, WT1 biology, active trials, transactions, unmet need, competition and market attractiveness.

2026 High-grade endometrial stromal sarcoma indication strategy covering epidemiology, YWHAE-NUTM2 biology, active trials, transactions, unmet need, competition…

2026 Uterine adenosarcoma indication strategy covering epidemiology, CDK4 biology, active trials, transactions, unmet need, competition and market attractiveness.

2026 Juvenile granulosa cell tumor indication strategy covering epidemiology, AKT1 biology, active trials, transactions, unmet need, competition and market…

2026 Sex cord tumor with annular tubules indication strategy covering epidemiology, STK11 biology, active trials, transactions, unmet need, competition and…

2026 Spermatocytic tumor indication strategy covering epidemiology, DMRT1 biology, active trials, transactions, unmet need, competition and market attractiveness.

2026 Embryonal carcinoma indication strategy covering epidemiology, KIT biology, active trials, transactions, unmet need, competition and market attractiveness.